|
GB9004781D0
(en)
*
|
1990-03-02 |
1990-04-25 |
Glaxo Group Ltd |
Device
|
|
GB9012870D0
(en)
*
|
1990-06-08 |
1990-08-01 |
Glaxo Group Ltd |
Device
|
|
GB9016789D0
(en)
*
|
1990-07-31 |
1990-09-12 |
Lilly Industries Ltd |
Medicament administering devices
|
|
US5042472A
(en)
*
|
1990-10-15 |
1991-08-27 |
Merck & Co., Inc. |
Powder inhaler device
|
|
US5337740A
(en)
*
|
1991-08-01 |
1994-08-16 |
New England Pharmaceuticals, Inc. |
Inhalation devices
|
|
DE19647947A1
(en)
*
|
1996-11-20 |
1998-05-28 |
Pfeiffer Erich Gmbh & Co Kg |
Discharge device for media
|
|
SE9900188D0
(en)
*
|
1999-01-22 |
1999-01-22 |
Astra Ab |
Dispensing device
|
|
US6810872B1
(en)
|
1999-12-10 |
2004-11-02 |
Unisia Jecs Corporation |
Inhalant medicator
|
|
CA2417825C
(en)
|
2000-08-05 |
2008-07-22 |
Glaxo Group Limited |
6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl)oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
|
|
US6759398B2
(en)
|
2000-08-05 |
2004-07-06 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative
|
|
GB0103630D0
(en)
|
2001-02-14 |
2001-03-28 |
Glaxo Group Ltd |
Chemical compounds
|
|
ATE381537T1
(en)
|
2001-03-22 |
2008-01-15 |
Glaxo Group Ltd |
FORMANILIDE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS
|
|
MY137522A
(en)
|
2001-04-30 |
2009-02-27 |
Glaxo Group Ltd |
Novel anti-inflammatory androstane derivatives.
|
|
EP1416990A1
(en)
*
|
2001-08-09 |
2004-05-12 |
Glaxo Group Limited |
Inhalation device with a pharmaceutical composition
|
|
SI2042168T1
(en)
|
2001-09-14 |
2014-01-31 |
Glaxo Group Limited |
Inhalation formulation comprising phenethanolamine derivatives for the treatment of respiratory diseases
|
|
US20030235538A1
(en)
|
2002-04-09 |
2003-12-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Method for the administration of an anticholinergic by inhalation
|
|
DE60318193T2
(en)
|
2002-04-25 |
2008-12-04 |
Glaxo Group Ltd., Greenford |
PHENETHANOLAMINDERIVATE
|
|
GB0217225D0
(en)
|
2002-07-25 |
2002-09-04 |
Glaxo Group Ltd |
Medicinal compounds
|
|
DE60320007T2
(en)
|
2002-10-28 |
2009-06-18 |
Glaxo Group Ltd., Greenford |
Phenthanolamine derivatives for the treatment of respiratory diseases
|
|
GB0303396D0
(en)
|
2003-02-14 |
2003-03-19 |
Glaxo Group Ltd |
Medicinal compounds
|
|
TW200519108A
(en)
|
2003-07-17 |
2005-06-16 |
Glaxo Group Ltd |
Muscarinic acetylcholine receptor antagonists
|
|
ATE494285T1
(en)
|
2003-10-14 |
2011-01-15 |
Glaxo Group Ltd |
MUSCARINE ACETYLCHOLINE RECEPTOR ANTAGONISTS
|
|
AR046114A1
(en)
|
2003-10-17 |
2005-11-23 |
Glaxo Group Ltd |
COMPOSITE OF 8- AZONIABICICLO (3.2.1) OCTOBER, PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES MEDIATED BY MUSCARINIC ACETILCOLINE RECEPTORS AND USE OF THE COMPOUND TO PREPARE SUCH COMPOSITION
|
|
PE20050489A1
(en)
|
2003-11-04 |
2005-09-02 |
Glaxo Group Ltd |
ANTAGONISTS OF MUSCARINE ACETYLCHOLINE RECEPTORS
|
|
GB0329182D0
(en)
|
2003-12-17 |
2004-01-21 |
Glaxo Group Ltd |
Chemical compounds
|
|
WO2005095407A1
(en)
|
2004-03-17 |
2005-10-13 |
Glaxo Group Limited |
M3 muscarinic acetylcholine receptor antagonists
|
|
US7846973B2
(en)
|
2004-04-02 |
2010-12-07 |
Theravance, Inc. |
Chemical process and new crystalline form
|
|
TWI363759B
(en)
|
2004-04-27 |
2012-05-11 |
Glaxo Group Ltd |
Muscarinic acetylcholine receptor antagonists
|
|
US7598267B2
(en)
|
2004-05-13 |
2009-10-06 |
Glaxo Group Limited |
Muscarinic acetylcholine receptor antagonists
|
|
JP5156397B2
(en)
|
2005-02-10 |
2013-03-06 |
グラクソ グループ リミテッド |
Method for producing lactose using preclassification technology and pharmaceutical preparation formed from the lactose
|
|
AR053346A1
(en)
|
2005-03-25 |
2007-05-02 |
Glaxo Group Ltd |
COMPOSITE DERIVED FROM 8H -PIRIDO (2,3-D) PIRIMIDIN -7 ONA 2,4,8- TRISUSTITUTED PHARMACEUTICAL COMPOSITION AND USE TO PREPARE A COMPOSITION FOR TREATMENT AND PROFILXIS OF A DISEASE MEDIATED BY KINASE CSBP / RK / P38
|
|
PE20100741A1
(en)
|
2005-03-25 |
2010-11-25 |
Glaxo Group Ltd |
COMPOUNDS DERIVED FROM 3,4-DIHYDROPYRIMIDE [4,5-d] PYRIMIDIN-2 (1H) -ONE AS KINASE INHIBITORS p38
|
|
WO2007022351A2
(en)
|
2005-08-18 |
2007-02-22 |
Glaxo Group Limited |
Muscarinic acetylcholine receptor antagonists
|
|
PE20081889A1
(en)
|
2007-03-23 |
2009-03-05 |
Smithkline Beecham Corp |
INDOL CARBOXAMIDES AS INHIBITORS OF IKK2
|
|
GB2463451A
(en)
|
2008-09-08 |
2010-03-17 |
Cambridge Lab |
3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
|
|
PL3578169T3
(en)
|
2009-02-26 |
2024-09-02 |
Glaxo Group Limited |
Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
|
|
JP2012530140A
(en)
|
2009-06-16 |
2012-11-29 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Novel [3,2-c] heteroaryl steroids, compositions and uses thereof as glucocorticoid receptor agonists
|
|
GB0921075D0
(en)
|
2009-12-01 |
2010-01-13 |
Glaxo Group Ltd |
Novel combination of the therapeutic agents
|
|
ES2546422T5
(en)
|
2010-08-31 |
2023-01-20 |
Glaxosmithkline Ip Dev Ltd |
Dry powder inhalation medicinal products having moisture control properties and methods of administration thereof
|
|
AU2011298409B2
(en)
|
2010-08-31 |
2013-11-21 |
Glaxo Group Limited |
Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
|
|
US9297813B2
(en)
|
2010-11-11 |
2016-03-29 |
Agency For Science, Technology And Research |
Targeting metabolic enzymes in human cancer
|
|
GB201116641D0
(en)
|
2011-09-27 |
2011-11-09 |
Glaxo Group Ltd |
Novel compounds
|
|
GB201207406D0
(en)
|
2012-04-27 |
2012-06-13 |
Glaxo Group Ltd |
Novel compounds
|
|
KR20150013463A
(en)
|
2012-04-27 |
2015-02-05 |
글락소 그룹 리미티드 |
Novel compounds
|
|
JP6270171B2
(en)
|
2012-11-28 |
2018-01-31 |
インターセプト ファーマシューティカルズ, インコーポレイテッド |
Treatment of lung disease
|
|
UY36578A
(en)
|
2015-03-11 |
2016-09-30 |
Glaxosmithkline Ip Dev Ltd |
TSLP JOINT PROTEINS
|
|
EA035864B1
(en)
|
2015-06-15 |
2020-08-21 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Nrf2 regulators
|
|
CN107709306A
(en)
|
2015-06-15 |
2018-02-16 |
葛兰素史密斯克莱知识产权发展有限公司 |
NRF2 modulator
|
|
JP6786527B2
(en)
|
2015-06-15 |
2020-11-18 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Nrf2 regulator
|
|
UY36851A
(en)
|
2015-08-16 |
2017-03-31 |
Glaxosmithkline Ip Dev Ltd |
COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS
|
|
US10351530B2
(en)
|
2015-10-06 |
2019-07-16 |
Glaxosmithkline Intellectual Property Development Limited |
Arylcyclohexyl pyrazoles as NRF2 regulators
|
|
JP2018529745A
(en)
|
2015-10-06 |
2018-10-11 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Biarylpyrazoles as NRF2 regulators
|
|
AU2017330620A1
(en)
|
2016-09-20 |
2019-03-28 |
Glaxosmithkline Intellectual Property (No.2) Limited |
TRPV4 antagonists
|
|
TW201825458A
(en)
|
2016-09-20 |
2018-07-16 |
英商葛蘭素史克智慧財產(第二)有限公司 |
TRPV 4 antagonists
|
|
JP2019532054A
(en)
|
2016-09-20 |
2019-11-07 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited |
TRPV4 antagonist
|
|
KR20190088404A
(en)
|
2016-12-06 |
2019-07-26 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
3- (2,3-dihydro-1H-inden-5-yl) propanoic acid derivatives and their use as NRF2 regulators
|
|
WO2018109641A1
(en)
|
2016-12-12 |
2018-06-21 |
Glaxosmithkline Intellectual Property Development Limited |
3-carboxylic acid pyrroles as nrf2 regulators
|
|
JP2020500918A
(en)
|
2016-12-12 |
2020-01-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
N-arylpyrazoles as NRF2 regulators
|
|
ES2848699T3
(en)
|
2016-12-14 |
2021-08-11 |
Glaxosmithkline Ip Dev Ltd |
3-Oxo-1,4-diazepinyl compounds as activators of NRF2
|
|
EP3555078B1
(en)
|
2016-12-14 |
2024-03-27 |
GlaxoSmithKline Intellectual Property Development Limited |
Bisaryl heterocycles as nrf2 activators
|
|
US11078216B2
(en)
|
2016-12-14 |
2021-08-03 |
Glaxosmithkline Intellectual Property Development Limited |
Bisaryl amides as NRF2 activators
|
|
WO2018109646A1
(en)
|
2016-12-15 |
2018-06-21 |
Glaxosmithkline Intellectual Property Development Limited |
Nrf2 compounds
|
|
JP2020502152A
(en)
|
2016-12-15 |
2020-01-23 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Ether-linked triazoles as NRF2 activators
|
|
PH12019502376B1
(en)
|
2017-04-24 |
2024-06-05 |
Cocrystal Pharma Inc |
Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
|
|
WO2019116231A1
(en)
|
2017-12-11 |
2019-06-20 |
Glaxosmithkline Intellectual Property Development Limited |
Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
|
|
WO2019116230A1
(en)
|
2017-12-11 |
2019-06-20 |
Glaxosmithkline Intellectual Property Development Limited |
Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
|
|
GB201720989D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
TWI795510B
(en)
|
2018-01-17 |
2023-03-11 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
PI4KIIIβ INHIBITORS
|
|
EP3796906A1
(en)
|
2018-05-23 |
2021-03-31 |
GlaxoSmithKline Intellectual Property Management Limited |
Indanes as nrf2 activators
|
|
TWI821343B
(en)
|
2018-07-27 |
2023-11-11 |
美商共結晶製藥公司 |
Inhibitors of influenza virus replication
|
|
CN113286793B
(en)
|
2018-09-10 |
2024-04-05 |
共结晶制药公司 |
Pyrrolopyrazine and pyridotriazine influenza virus replication inhibitors
|
|
MX2021004215A
(en)
|
2018-10-17 |
2021-07-15 |
Cocrystal Pharma Inc |
COMBINATIONS OF INHIBITORS OF THE REPLICATION OF THE INFLUENZA VIRUS.
|
|
CA3119145A1
(en)
|
2018-11-13 |
2020-05-22 |
Cocrystal Pharma, Inc. |
Formulations comprising 3-(2-(5-chloro-1h-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7h-pyrrolo[2,3-d]pyrimid-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid for the treatment of influenza
|
|
WO2020112716A1
(en)
|
2018-11-26 |
2020-06-04 |
Cocrystal Pharma, Inc. |
Inhibitors of influenza virus replication
|
|
GB201908536D0
(en)
|
2019-06-13 |
2019-07-31 |
Glaxosmithkline Ip Dev Ltd |
Compounds
|
|
US20230151034A1
(en)
|
2020-03-17 |
2023-05-18 |
Cocrystal Pharma, Inc. |
Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication
|
|
TW202204318A
(en)
|
2020-04-10 |
2022-02-01 |
美商共結晶製藥公司 |
Inhibitors of norovirus and coronavirus replication
|
|
EP4138884A1
(en)
|
2020-04-20 |
2023-03-01 |
Sorrento Therapeutics, Inc. |
Pulmonary administration of ace2 polypeptides
|
|
WO2022175425A1
(en)
|
2021-02-22 |
2022-08-25 |
Glaxosmithkline Intellectual Property Development Limited |
Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
|
|
WO2022179967A1
(en)
|
2021-02-23 |
2022-09-01 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Vadadustat for treating covid-19 in a hospitalized subject
|
|
KR20240055745A
(en)
|
2021-08-03 |
2024-04-29 |
코크리스탈 파마, 아이엔씨. |
coronavirus inhibitor
|